Antibacterial Agents TRIZ Cases

Novel triazole inhibitors degrade oncogenic proteins like c-Kit and EGFR, overcoming multidrug resistance in cancer treatment.

A pyridinium ionic liquid catalyzes a one-pot four-component reaction to form an imidazole derivative with strong antimicrobial activity.

Novel compounds inhibit cytochrome bc1 activity to target Mycobacterium tuberculosis.

Fucosylated human milk oligosaccharides prevent antibiotic-associated diarrhea by promoting beneficial bacteria and reducing pathogenic load.

Nitrogen-containing fused ring compounds act as potent CRTH2 antagonists with high selectivity.

Segmenting monocytes by Cd49f, Cd54, and Cd11b expression resolves functional heterogeneity detection limits to enhance bacterial killing efficacy.

Novel heterocyclic compounds inhibit MEK enzymes to disrupt the Ras/Raf kinase signaling pathway.

Combining fecal lactoferrin measurement with toxin detection resolves the trade-off between diagnostic accuracy and disease severity information loss.

Compounds inhibit picornavirus 2C protein ATPase activity to block viral RNA replication and encapsidation.

Iodine-carbohydrate-protein complexes penetrate bacterial membranes to kill resistant strains while protecting host tissues from toxicity.

Semi-permeable membrane filtration removes virucidal particles from PCV-2 antigens, enabling safe combination with other immunogens in multivalent vaccines.

Antisense morpholino oligomers target bacterial virulence genes to restore antibiotic susceptibility in resistant pathogens.

Inside-out tethered light chains force heterodimeric assembly, eliminating random homodimer formation and simplifying purification.

Tricyclic heterocyclic compounds with defined substituents selectively target bacteria while minimizing mammalian cell toxicity.

Silver and ruthenium particles generate reactive oxygen species to kill pathogens, shortening herpes outbreak duration.

2-quinolinylhydrazone derivatives inhibit Mycobacterium tuberculosis growth, addressing drug-resistant strains and reducing treatment duration.

Bacteriophage display mutates T cell receptor chains to overcome low affinity from central tolerance, enabling specific tumor targeting.

SIRP-α variants with cleavable linkers selectively bind CD47 in acidic tumor microenvironments, reducing off-target effects.

Dispersing silver salts in the water phase during manufacturing provides sustained antimicrobial activity while managing process complexity.

Tellimagrandin II polyphenol overcomes MRSA antibiotic resistance and reduces inflammation by regulating nitric oxide production.

Photoactivated oxidant composition generates reactive oxygen species to destroy periodontal bacteria.

Formula I compounds inhibit Syk kinase activity, addressing insufficient therapeutic efficacy of monotherapy when combined with vinca-alkaloids.

A ginsenoside-based blank liposome membrane encapsulates active substances with high efficiency.

Overexpressing GnTIII modifies antibody glycosylation to enhance Fc receptor binding, resolving limited effector function in B cell lymphoma treatments.

High-concentration aqueous sulfomethylated polymyxin maintains long-term room temperature stability while preventing toxic colistin formation.

Forced convection through surface immobilized polysaccharides removes blood cytokines without diffusive transport delays.

Proteomic analysis identifies specific bacterial protein profiles to distinguish pathogens from commensal flora in chronic sinusitis samples.

Modified bacteriophage uses hybrid tail fibers and SASP genes to treat multi-drug resistant infections without inducing antibiotic resistance.

Bacteriophage and lytic protein compositions target Staphylococcus aureus biofilms to dismantle the protective extracellular matrix structure.

Azetidinyl diamides inhibit monoacylglycerol lipase to elevate endocannabinoid signaling, avoiding synthetic cannabinoid side effects.

Macrocyclic peptides bind PD-L1 to block immune evasion and restore T cell function.

A dual adjuvant vaccine system combines a water-in-oil-in-water emulsion with aluminum hydroxide to encapsulate antigens and enhance immune responses.

Simultaneous blockade of co-inhibitory pathways overcomes single-agent limitations and simplifies therapeutic regimens.

Encoding IL-28 alongside immunogens overcomes weak cellular immunity by enhancing CD8 T cell activity and interferon gamma release.

Myoviridae bacteriophage Clo-PEP-1 infects and lyses Clostridium perfringens cells via natural replication cycles.

Zeolites adsorb nitric oxide gas to enable controlled release, reducing systemic toxicity from gaseous delivery.

Engineered bacteria deliver quorum quenching molecules to degrade Vibrio signals, reducing EMS mortality without antibiotic resistance.

Adeno-associated virus vectors deliver urocortin 2 genes to treat type I diabetes, replacing frequent protein infusions with sustained paracrine expression.

A porous polyolefin coating on HPPE yarn maintains tensile strength while enabling controlled bioactive release for surgical sutures.

Recombinant LysSS protein degrades bacterial peptidoglycan cell walls to kill pathogens.

Pyrimido-diazepinone compounds inhibit specific kinases like MPS1 and ERK5, resolving the trade-off between broad coverage and precise targeting.

G:U wobble base pairs in double-stranded RNA sections enable selective TLR7 activation and high type I IFN production without transfection reagents.

Cleavable linkers segment active molecules from PEG carriers, resolving the trade-off between prolonged half-life and reliable drug release.

A recombinant human IgG1 antibody with modified CH2 and CH3 domains enhances complement-dependent cytotoxic activity.

Zirconium phosphate hosts silver ions to resolve heat resistance and resin coloring trade-offs.

Genetic engineering of polymyxin E synthetase gene clusters modifies peptide structures to produce antibiotic variants with reduced toxicity.

Thickened otic gel formulation retains active ingredients in the ear canal, preventing rapid egress and enabling single-dose treatment of fungal infections.

Engineered cell surface conjugates enable precise detection and modulation of therapeutic immune cells without triggering intracellular activation.

Doping emulsion phases with carbohydrates during spray drying produces spherical nanoparticles with narrow size distribution.